Search results for: 'comparative distributed energy'

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

This study by Frost & Sullivans Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants. T...

19 Feb 2021  |  North America  |  Market Research

Regulatory and Infrastructure Reforms in India and China Catalyzing the Asian Specialty Generics Market

High Unmet Needs in Niche Oncology Indications will Drive Future Growth Potential

Infographics

×

Frost & Sullivans Transformational Health team provides critical insights into the Asian specialty generics market with this research service, highlighting growth opportunities, selected countries biopharmaceutical environment, and significant R&D, regulatory, and infrastructure reforms influencing its growth. The report examines similarities and c...

05 Apr 2023  |  Asia Pacific  |  Market Outlook

Asia-Pacific Pharmaceutical Industry Outlook, 2023

Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

Infographics

×

Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan,...

Despite the term patient centricity gaining currency in the industry, there is a degree of variability in a companies’ approach and strategic priorities. Frost & Sullivan sees digitization playing a critical role in transforming the clinical trial model from traditional, high-cost, and difficult-to-access centralized settings to more patient-centri...

Therapeutically more effective drugs for the treatment of chronic diseases represents a crucial need. Biosimilars and biobetters offer the possibility to lower the cost of treating a variety of chronic diseases. In particular, biosimilars are the less expensive option; however, biobetters have demonstrated to be more effective, even over longer per...

27 Aug 2020  |  Global  |  Market Research

Smart Labs as Key Drivers for the Digital Transformation of Diagnostic Laboratories, 2020

Robotic Automation, Internet of Things (IoT), and Artificial Intelligence (AI) Offering Growth Opportunities for Academic and Commercial Diagnostics Labs

Infographics

×

Key Issues Addressed

Diagnostic academic and commercial research labs suffer from cost pressures, given the ongoing Protecting Access to Medicare Act (PAMA) regulations and reproducibility issues, and are under productivity strain. The recent COVID-19 pandemic leading to increasing test volumes and renewed focus on research and development (R&D) to drive innovation wil...

Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

Medicine production supply chains are currently operating under huge stress due to the war in Ukraine, COVID-19-related disruptions, logistics bottlenecks, and inflation. An energy-related shutdown of production would have a detrimental effect on the supply of critical medicines to patients in the EU and worldwide. The excessive amount of pressure ...